TCGA-33-AASB-01A-11R-A405-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.380
- MYC_TARGETS_V2+0.370
- OXIDATIVE_PHOSPHORYLATION+0.330
- MTORC1_SIGNALING+0.310
- UV_RESPONSE_UP+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- GLYCOLYSIS+0.270
- MYC_TARGETS_V1+0.230
- XENOBIOTIC_METABOLISM+0.230
- ESTROGEN_RESPONSE_EARLY+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_GAMMA_RESPONSE-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- UV_RESPONSE_DN-0.370
- INFLAMMATORY_RESPONSE-0.350
- KRAS_SIGNALING_UP-0.310
- IL2_STAT5_SIGNALING-0.290
- TGF_BETA_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-AAS8-01A-11R-A405-07 | — | cohortSQ2 | 0.862 |
| 2 | TCGA-CV-6962-01A-11R-1915-07 | — | — | 0.845 |
| 3 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.842 |
| 4 | SRR8613749 | — | C | 0.842 |
| 5 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.841 |
| 6 | SRR2669446 | — | — | 0.836 |
| 7 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.827 |
| 8 | TCGA-39-5027-01A-21R-1820-07 | — | cohortSQ2 | 0.826 |
| 9 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.824 |
| 10 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |